Overview
TRZ-2 identifies tirzepatide, the active molecule in branded Mounjaro and Zepbound. FDA approval is specific to branded preparations and their indications; this compounded preparation is not either product5.
The randomized evidence supports concrete population-level outcomes, with accompanying tolerability and safety information. It does not make a study average an individual prediction or establish identical exposure from a compounded vial1,4,5.
Dual-incretin development
Tirzepatide was designed to engage both GIP and GLP-1 receptors with a modified incretin-associated peptide. A lipid-containing modification enables prolonged albumin-associated exposure5.
The SURPASS and SURMOUNT programs addressed different clinical populations and endpoints. Diabetes outcomes, obesity outcomes and active-comparator results should be read within their actual trial settings1,2,4.
Mechanism of action
Dual receptor activity influences appetite-related circuits and glucose-dependent insulin secretion. These effects connect reduced intake with metabolic regulation without implying that weight reduction occurs independently of food intake2,5.
Delayed gastric emptying is strongest early in treatment and can affect oral-drug absorption. This mechanism also makes gastrointestinal symptoms and contraception counselling clinically important5.
- 1Activates two incretin receptorsTirzepatide is a single peptide that activates both GIP and GLP-1 receptors, combining two gut-hormone signals5.
- 2Reduces appetiteSignalling in appetite-regulating pathways lowers hunger and calorie intake, driving sustained weight loss1,5.
- 3Improves glucose controlGlucose-dependent insulin secretion lowered HbA1c by up to 2.30 percentage points, more than semaglutide in SURPASS-22.
- 4Slows digestion, lasts all weekIt delays gastric emptying, and an albumin-binding fatty-acid side chain extends its half-life to support once-weekly dosing5.
- GIP receptor
- GLP-1 receptor
- Appetite circuits
- Glucose-dependent insulin secretion
- Gastric emptying
Weight, glycemia & maintenance
SURMOUNT-1 randomized 2,539 adults without diabetes. At 72 weeks, the highest-dose arm averaged 20.9% weight reduction versus 3.1% with placebo; results occurred with trial supervision and lifestyle intervention1.
SURMOUNT-5 randomized 751 adults without diabetes and compared maximum tolerated study doses. At 72 weeks, mean reductions were 20.2% with tirzepatide and 13.7% with semaglutide; the trial was open-label, and its comparison should not be generalized to every dose4.
In SURMOUNT-4, participants switched to placebo regained weight, while continuing recipients maintained and extended their initial reduction. This informs discussion of maintenance rather than promising a permanent reset after stopping3.
20.9% average weight loss1
SURMOUNT-1’s top dose averaged 20.9% weight loss at 72 weeks versus 3.1% with placebo, and 57% on 10–15 mg lost a fifth of their weight.
Beats semaglutide head to head4
In SURMOUNT-5, tirzepatide produced 20.2% weight loss versus 13.7% with semaglutide at 72 weeks.
Superior glucose control2
In SURPASS-2, all three doses lowered HbA1c more than semaglutide, with greater weight reduction.
Lasting results3
In SURMOUNT-4, 89.5% of people who stayed on tirzepatide kept at least 80% of their weight loss at 88 weeks, versus 16.6% on placebo.
Safety & monitoring
The label carries a boxed thyroid C-cell tumor warning, including contraindications for personal or family medullary thyroid carcinoma or MEN2. Human causality of the rodent tumor finding is not established, but the contraindications remain relevant5.
Severe gastrointestinal effects, dehydration-related kidney injury, gallbladder disease, pancreatitis, hypersensitivity and hypoglycemia with relevant other therapies require review. Pregnancy, oral contraception and planned anesthesia or deep sedation should be discussed with the provider5.
- This compounded preparation is not FDA-approved Mounjaro or Zepbound.
- Branded labeling contraindicates personal/family medullary thyroid carcinoma or MEN2 and serious hypersensitivity [5].
- Review severe gastrointestinal symptoms, pancreatitis, gallbladder disease and dehydration risks [5].
- Insulin or insulin secretagogues can increase hypoglycemia risk; medication review is required [5].
- Discuss pregnancy, oral contraception, other incretin products and procedures involving anesthesia [5].
Supply, storage & administration
Branded tirzepatide is supplied as a ready-to-use subcutaneous liquid; this compounded preparation is not that product5. Confirm whether your pharmacy dispenses powder or liquid, the actual concentration and its own storage and reconstitution instructions.
The catalog specifies vial content, not a verified final formulation or storage specification. A lyophilized preparation requires the pharmacy-specified compatible diluent; a ready-to-use liquid does not. Follow the dispensing label for refrigeration, light protection and the beyond-use date, and use aseptic technique with a new sterile needle and syringe6. Dosing is set by your provider.
Questions
TRZ-2 or RT-3?
Tirzepatide is a dual GIP/GLP-1 agonist with approved branded drugs. Retatrutide adds glucagon-receptor activity and remains investigational; cross-trial averages do not prove superiority.
Will I lose the trial average?
No. Results vary with population, exposure, adherence, tolerance and other factors; a mean is not a personal guarantee.
Is compounded tirzepatide approved?
No. Approval of Mounjaro or Zepbound does not approve this preparation or establish its clinical equivalence.
Does the comparison prove every dose is better?
No. SURMOUNT-5 used specific maximum tolerated study doses in a defined population.
What happens after stopping?
Withdrawal research found substantial regain, supporting a provider-led discussion of maintenance.
References
- 1.Phase 3 RCT
Tirzepatide Once Weekly for the Treatment of Obesity. (opens in a new tab)
Jastreboff AM, Aronne LJ, Ahmad NN, et al.. The New England journal of medicine, 2022. PMID 35658024
SURMOUNT-1 randomized 2,539 adults; highest-dose mean weight reduction was 20.9% at 72 weeks versus 3.1% with placebo.
- 2.Phase 3 RCT
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. (opens in a new tab)
Frías JP, Davies MJ, Rosenstock J, et al.. The New England journal of medicine, 2021. PMID 34170647
SURPASS-2 compared tirzepatide with semaglutide in type 2 diabetes and measured HbA1c and weight outcomes.
- 3.Phase 3 RCT
Aronne LJ, Sattar N, Horn DB, et al.. JAMA, 2024. PMID 38078870
SURMOUNT-4 found regain after withdrawal and continued maintenance with ongoing tirzepatide.
- 4.Phase 3 RCT
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. (opens in a new tab)
Aronne LJ, Horn DB, le Roux CW, et al.. The New England journal of medicine, 2025. PMID 40353578
SURMOUNT-5 randomized 751 adults; mean reductions at 72 weeks were 20.2% versus 13.7% with semaglutide at the studied doses.
- 5.Guidance / label
ZEPBOUND (tirzepatide) injection: prescribing information (opens in a new tab)
Eli Lilly and Company; U.S. Food and Drug Administration. Regulatory guidance / prescribing information, 2026.
FDA prescribing information for Zepbound: indications, the boxed thyroid C-cell tumor warning, and gastrointestinal, pancreatic and gallbladder precautions.
- 6.Guidance / label
Preventing Unsafe Injection Practices (opens in a new tab)
Centers for Disease Control and Prevention. Regulatory guidance / prescribing information, 2024.
Use aseptic technique and a new sterile needle and syringe; opened multi-dose vials generally have a 28-day discard window unless the manufacturer specifies otherwise, never beyond original expiration.
Research summaries are educational and describe published studies, many in animal or cell models. They are not claims that this product treats any condition. Compounded medications are prepared by a licensed 503A pharmacy for individual patients and are not FDA-approved. Statements on this site have not been evaluated by the FDA. Products are dispensed only after review by a licensed provider. This site does not provide medical advice; talk to your provider before starting any therapy.